Results 211 to 220 of about 3,831 (231)

Meropenem/vaborbactam cost effective in Italy

PharmacoEconomics & Outcomes News, 2021
openaire   +1 more source

Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections

Clinical Infectious Diseases, 2020
Ryan K Shields, Erin K Mccreary, Ellen G Kline   +2 more
exaly  

Flow Synthesis of Vaborbactam

Synfacts, 2019
openaire   +1 more source

Immune-globulin/meropenem/vaborbactam

Reactions Weekly, 2020
openaire   +1 more source

Meropenem–Vaborbactam

Reactions Weekly
openaire   +2 more sources

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2018
Meredith A Hackel, Olga Lomovskaya, Michael N Dudley   +2 more
exaly  

Avibactam/ceftazidime/colistin/meropenem/vaborbactam

Reactions Weekly, 2020
openaire   +1 more source

Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2019
Ellen G Kline, Yohei Doi, M Hong Nguyen
exaly  

Vaborbactam. Beta-Lactamase inhibitor, Antibacterial agent

Drugs of the Future, 2016
null Thakare, R., null Dasgupta, A., null Chopra, S.   +2 more
openaire   +1 more source

Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

Antimicrobial Agents and Chemotherapy, 2020
Danya Roshdy
exaly